Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 25, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 28, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001839111-26-000001
Filed / recorded
Feb 28, 2026, 2:05 AM UTC
Added to OQRO
Oct 8, 2026, 1:45 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Health Catalyst, Inc.
Issuer CIK
1636422
Ticker
HCAT
Reporting person
Jason Alger
Relationship
Officer
Officer title
Chief Financial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 25, 2026
Transaction code
A
Shares / units
22,222
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
776,136
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents an award of 22,222 performance-based restricted units ("PRSUs") pursuant to the 2019 Plan, based upon the Issuer's satisfaction of certain performance criteria for the fiscal year ended December 31, 2025. Each PRSU represents a contingent right to receive one share of the Issuer's common stock.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Changed a top executive or board member, and reported other company news
“On April 24, 2026, the Board of Directors (our Board) of Health Catalyst, Inc. (the Company) determined that Linda Llewelyn will cease to serve as the Chief People Officer of the Company effective June 1, 2026 due to the elimination of the Chief People Officer role in connection with the workforce reduction described in this Current Report on Form 8-K. In order to enable a smooth transition of her prior…”
